Inotrem | News

May 5, 2025

Inotrem announces the publication of the results of its mechanism-based prognostic approach for nangibotide in septic shock

Paris (France), May 5th. 2025. Inotrem, XXX

January 8, 2024

Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock

Paris (France), January 8. 2024. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, today announced the outcome of its regulatory interactions with the US Food and Drug Administration (FDA) to finalize the design of a single Phase 3 registration trial (ACCURATE) for

Press Releases

Inotrem announces the publication of the results of its mechanism-based prognostic approach for nangibotide in septic shock

Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock

Inotrem receives milestone funding from the Crohn’s & Colitis Foundation

Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals

Winner of the French Tech 120!

Inotrem Receives Funding from the Crohn’s & Colitis Foundation to help develop new therapeutic approaches in Inflammatory Bowel Disease (IBD)

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

Inotrem announce the appointment of Luke Beshar as Chairman of Board of Directors

Inotrem and the Crohn’s & Colitis Foundation sign a R&D collaboration agreement to support the development of a new therapeutic approach in Inflammatory Bowel Disease (IBD)

Inotrem appoints Laurent Vincens as Chief Technology Officer and Head of Manufacturing

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Inotrem appoints Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program Targeting Chronic Inflammatory Diseases

Inotrem receives approval to expand nangibotide clinical trial in critically ill COVID-19 patients and receive additional public funding of €45 million

Inotrem adds a new strategic asset to its immunotherapy anti-TREM-1 drug pipeline

Inotrem announces positive outcome of interim futility analysis for its Phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy

Inotrem bolsters leadership team with the appointment of Sven Zimmermann as new CEO

CoviTREM-1 consortium, composed of Inotrem, Nancy and Limoges teaching hospitals, announces it has completed patients’ inclusion for its COVID-19 Phase IIa clinical study

Inotrem’s COVID-19 Phase IIa Clinical Trial declared “National Priority Research” by the French government’s Clinical Trial Council

Inotrem announces Data Monitoring Committee (DMC) recommends continuation of Phase IIa study of nangibotide for the treatment of severe forms of COVID-19

First Patients Enrolled in the CoviTREM-1 Program

Inotrem expands its Leadership Team with the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and of Simon Lambden as Head of Medical Science

Inotrem receives clearance from French, Belgian and US authorities to launch a Phase II clinical trial aimed at assessing nangibotide in mechanically ventilated patients with COVID-19

Inotrem announces the publication of its Phase IIa clinical study for nangibotide in the treatment of septic shock in peer review journal “Intensive Care Medicine”

Inotrem expands Series B financing to €58 Million with a mix of Equity and Debt, adding new investors Fountain Healthcare Partners, Kreos and Bpifrance

Inotrem was chosen to join the French Tech 120

Inotrem secures strategic licensing agreement for a companion diagnostics test in septic shock.

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock

Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics

Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide development program for the Treatment of Septic Shock

Inotrem announces FDA clearance of Investigational New Drug (IND) for the phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy

Inotrem announces positive results from the Phase IIa study of its lead compound, nangibotide (LR12), in the treatment of septic shock.

Martin Koch joins Inotrem as Chief Operating Officer

Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.

Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test

Inotrem announces new preclinical data supporting its lead compound’s (LR12) positive role on vascular dysfunction during septic shock

Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock.

Inotrem Raises €18 million to Develop Innovative Sepsis Treatments in a Series A Financing Co-led by Edmond de Rothschild Investment Partners and Sofinnova Partners